Pfizer moves obesity drug berobenatide to Phase 3 after mid-stage data disappoints

Pfizer's experimental obesity drug berobenatide produced mid-stage results that disappointed investors, and the company's share price fell after the data came out. Pfizer is moving the drug into Phase 3 testing anyway.

Berobenatide, also called PF-08653944, came to Pfizer through its acquisition of Metsera, a deal valued at roughly $10 billion. It is being developed for people who are overweight or obese. A study of the drug in that population is listed on ClinicalTrials.gov under the identifier NCT07595549 ^[1].

The specific Phase 2b results have not been confirmed from a primary source. Pfizer has not released verified efficacy and safety figures — not the average weight loss, not the doses tested, not the number of participants, and not any comparison against a placebo or an active comparator. How the trial was designed, how long it ran, and what it measured also have not been disclosed. Without those numbers, it is not possible to say how berobenatide's mid-stage performance compares with that of medicines already on the market or with other experimental drugs.

What is known is the direction of travel: the program is advancing to Phase 3. That is the last stage of testing before a company can seek FDA approval, and it usually involves hundreds to several thousand participants followed for a year or more. No start date, target enrollment, or list of trial sites for the Phase 3 program has been announced.

A disappointing investor reaction at the mid-stage point does not settle whether a drug works. Phase 2 trials are often small and are built to look for a signal, not to prove a benefit, and results can look better or worse than they do later in larger studies. Still, a weak readout can reshape a drugmaker's timeline for a new obesity treatment. Pfizer's decision to keep going suggests it sees enough to justify the cost of late-stage testing.

Why it matters for patients

Berobenatide is not approved and is not available by prescription. Nothing about this readout changes the medicines patients can already get, such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), or how they are taken.

For people deciding among treatments that exist today, this news has no practical effect. It matters mainly as a signal about how crowded and competitive the obesity drug pipeline is, and how quickly a promising candidate can stumble before regulators ever see it.

More new drugs can mean more choices and, eventually, more price competition. A candidate that stalls or fails removes one of those future options. Patients who are waiting for a new alternative — a different dosing schedule, a different side effect profile, or a lower cost — may have to wait longer if a program slows down.

This is also a reminder about how early-stage news should be read. A share price move reflects investor expectations, not trial data that has been reviewed by regulators or published in full. The registry listing for the berobenatide study in people who are overweight or obese, NCT07595549, is the place where design and enrollment details are posted as they become available ^[1].

What happens next

Watch for Pfizer to release the Phase 2b numbers in full, to announce when Phase 3 begins, and to update the ClinicalTrials.gov listing for berobenatide ^[1] with enrollment targets and study sites. Until those details appear, the strength of the mid-stage results has not been established. It has also not been disclosed whether Pfizer plans to test berobenatide against an existing obesity medicine or against a placebo in the next round of trials.